ADMA Biologics, Inc. (NASDAQ:ADMA) Position Trimmed by Ashton Thomas Private Wealth LLC

Ashton Thomas Private Wealth LLC trimmed its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 24.3% during the third quarter, Holdings Channel reports. The firm owned 17,034 shares of the biotechnology company’s stock after selling 5,458 shares during the quarter. Ashton Thomas Private Wealth LLC’s holdings in ADMA Biologics were worth $341,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. D. E. Shaw & Co. Inc. grew its position in shares of ADMA Biologics by 26.8% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock valued at $76,298,000 after buying an additional 1,442,799 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in ADMA Biologics by 2.7% in the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after acquiring an additional 92,281 shares during the period. Driehaus Capital Management LLC grew its holdings in shares of ADMA Biologics by 17.3% during the second quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company’s stock valued at $33,860,000 after purchasing an additional 447,743 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of ADMA Biologics by 28.7% during the 2nd quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company’s stock worth $28,868,000 after purchasing an additional 575,100 shares during the period. Finally, Federated Hermes Inc. lifted its holdings in shares of ADMA Biologics by 15.5% in the 2nd quarter. Federated Hermes Inc. now owns 1,969,811 shares of the biotechnology company’s stock worth $22,022,000 after purchasing an additional 263,677 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Stock Down 5.9 %

ADMA opened at $20.20 on Friday. The stock’s 50 day moving average price is $18.42 and its 200 day moving average price is $14.22. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The stock has a market cap of $4.71 billion, a P/E ratio of 72.14 and a beta of 0.64. ADMA Biologics, Inc. has a 12 month low of $3.60 and a 12 month high of $23.64.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company had revenue of $119.84 million during the quarter, compared to analysts’ expectations of $107.25 million. During the same quarter in the prior year, the business posted $0.01 earnings per share. As a group, research analysts predict that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

Wall Street Analyst Weigh In

ADMA has been the subject of a number of recent research reports. HC Wainwright upped their price objective on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Raymond James upped their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th.

Insider Buying and Selling at ADMA Biologics

In related news, Director Lawrence P. Guiheen sold 9,000 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the transaction, the director now owns 153,941 shares of the company’s stock, valued at $2,843,290.27. This trade represents a 5.52 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $16.90, for a total transaction of $408,135.00. Following the completion of the sale, the chief operating officer now owns 449,088 shares in the company, valued at approximately $7,589,587.20. This trade represents a 5.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 466,900 shares of company stock valued at $8,224,121. Company insiders own 3.70% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.